logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 8975439 B1

PDFFull Text
Date of Patent:
Mar. 10, 2015

Filed:

Nov. 30, 2012

Arylsulfonamide based matrix metalloprotease inhibitors

Applicant:

Novartis Ag, Basel, CH;

Inventors:

Ruben Alberto Tommasi, Stow, MA (US);

Michael David Shultz, Lexington, MA (US);

Leslie Wighton McQuire, Warren, NJ (US);

Pascal Rigollier, Hegenthal-le-Bas, FR;

Olivier Rogel, Hésingue, FR;

Claus Ehrhardt, Lörrach, DE;

Assignee:

Novartis AG, Basel, CH;

Attorney:

Sophie Binet-Cross

Primary Examiner:

Robert Havlin

Int. Cl.
CPC ...
C07C 311/16 (2006.01); A61K 31/18 (2006.01); C07D 207/333 (2006.01); C07D 209/12 (2006.01); C07C 317/24 (2006.01); C07D 295/112 (2006.01); A61K 45/06 (2006.01); C07D 403/04 (2006.01); C07D 409/04 (2006.01); A61K 31/55 (2006.01); C07D 209/82 (2006.01); C07D 235/06 (2006.01); C07D 241/04 (2006.01); C07C 323/67 (2006.01); C07D 211/14 (2006.01); C07D 265/30 (2006.01); C07D 211/06 (2006.01); C07D 213/61 (2006.01); C07D 213/50 (2006.01); C07D 471/04 (2006.01); C07D 209/14 (2006.01); C07D 211/24 (2006.01); C07D 209/08 (2006.01); C07D 209/10 (2006.01); C07D 333/22 (2006.01); A61K 31/4402 (2006.01); C07D 401/04 (2006.01); C07D 295/116 (2006.01); C07C 311/46 (2006.01); C07D 223/04 (2006.01); C07D 333/18 (2006.01); C07D 413/04 (2006.01); C07D 221/16 (2006.01); C07D 295/192 (2006.01); C07D 207/20 (2006.01); A61K 31/451 (2006.01); C07D 209/80 (2006.01); A61K 31/437 (2006.01); C07D 213/40 (2006.01); C07C 311/29 (2006.01); C07D 487/04 (2006.01); C07D 231/56 (2006.01); A61K 31/495 (2006.01); C07C 311/39 (2006.01); C07D 235/08 (2006.01); A61K 31/5375 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5375 (2013.01); C07D 207/333 (2013.01); C07D 209/12 (2013.01); C07C 317/24 (2013.01); C07D 295/112 (2013.01); A61K 45/06 (2013.01); C07D 403/04 (2013.01); C07D 409/04 (2013.01); A61K 31/55 (2013.01); C07D 209/82 (2013.01); C07D 235/06 (2013.01); C07D 241/04 (2013.01); C07C 323/67 (2013.01); C07D 211/14 (2013.01); C07C 2101/02 (2013.01); C07C 2102/08 (2013.01); C07D 265/30 (2013.01); C07D 211/06 (2013.01); C07D 213/61 (2013.01); C07D 213/50 (2013.01); C07D 471/04 (2013.01); C07D 209/14 (2013.01); C07C 2101/08 (2013.01); C07D 211/24 (2013.01); C07D 209/08 (2013.01); C07D 209/10 (2013.01); C07D 333/22 (2013.01); C07C 2101/14 (2013.01); A61K 31/18 (2013.01); A61K 31/4402 (2013.01); C07D 401/04 (2013.01); C07D 295/116 (2013.01); C07C 311/46 (2013.01); C07D 223/04 (2013.01); C07D 333/18 (2013.01); C07C 311/16 (2013.01); C07D 413/04 (2013.01); C07D 221/16 (2013.01); C07D 295/192 (2013.01); C07D 207/20 (2013.01); A61K 31/451 (2013.01); C07D 209/80 (2013.01); A61K 31/437 (2013.01); C07D 213/40 (2013.01); C07C 311/29 (2013.01); C07D 487/04 (2013.01); C07D 231/56 (2013.01); A61K 31/495 (2013.01); C07C 311/39 (2013.01); C07D 235/08 (2013.01);
Abstract

The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.

Find Patent Forward Citations

Loading…